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Abstract
Background: The Disease Severity Scoring System (DS3) is a validated measure for evaluating Gaucher disease type
1 (GD1) severity. We developed a new framework, consisting of health states, transition probabilities between those
states, and preferences for those states (utilities) based on the DS3 to predict long-term outcomes of patients
starting treatment. We defined nine mutually exclusive (alive) health states based on three DS3 categories: mild (0
≤ DS3 ≤ 3.5) without symptoms of bone disease; mild with bone pain, mild with severe skeletal complications
(SSC) defined as lytic lesions, avascular necrosis, or fracture; moderate (3.5 < DS3 ≤ 6.5) without SSC; moderate with
SSC; marked (6.5 < DS3 ≤ 9.5) without SSC; marked with SSC; severe (9.5 < DS3 ≤ 19) without SSC; and severe with
SSC. Health-state transition probabilities and utilities were estimated from a longitudinal sample of patients with
GD1 who started enzyme replacement therapy (the DS3 Score Study). Age dependent GD1-specific mortality was
derived from published data. We used a Markov state-transition model to illustrate how to estimate time spent in
each health state.
Results: The average predicted utilities for each health state ranged from 0.76 for mild disease with no clinical
symptoms of bone disease to 0.52 with severe disease with SSC. Transition probabilities depended on disease
severity (DS3 score) at treatment initiation and whether patients had undergone a total splenectomy or had an
intact spleen/partial splenectomy prior to starting treatment. Patients who started treatment with intact or residual
spleens spent more time in better health states than those who started treatment with total splenectomy.
Conclusions: This new framework, which is based on the DS3, can be used to project the long-term outcomes of
GD1 patients starting treatment. The framework could also be used to compare the long-term outcomes of
different GD1 treatment options.
Trial registration: NCT01136304. Registered: May 31, 2010 (retrospectively registered).
Keywords: Gaucher disease, Simulation, Health-related quality-of-life, Economic evaluation
Background
Gaucher disease (GD) is an autosomal recessive lyso-
somal storage disorder caused by deficient glucocerebro-
sidase activity [1]. The disease is rare, occurring in about
1 in 100,000 births worldwide and 1 in 850 among
Ashkenazi Jews [2]. The most prevalent form is Gaucher
disease type 1 (GD1) which accounts for up to 95% of
cases [3]. Presentation of the disease is variable, but is
typically characterized by visceral problems such as
splenomegaly and hepatomegaly, hematologic issues
such as anemia and thrombocytopenia, and skeletal
complications such as severe bone pain, avascular necro-
sis, and joint deformities, or loss in bone mineral density
with increased risk of bone fragility fractures [1, 4–6].
Current therapeutic options with regulatory approval in
either the United States (US) or Europe include intraven-
ous enzyme replacement therapy (ERT) with imiglucerase,
velaglucerase alfa, or (in the US only) taliglucerase alfa or
oral substrate reduction therapy (SRT) with eliglustat or
miglustat [7]. Imiglucerase was licensed in the early 1990s
[8] and has been shown to reverse the signs and
* Correspondence: michael.ganz@evidera.com
1Evidera, 500 Totten Pond Road, 5th Floor, Waltham, MA 02451, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ganz et al. Orphanet Journal of Rare Diseases  (2017) 12:38 
DOI 10.1186/s13023-017-0592-6
symptoms of GD1, laboratory and imaging abnormalities,
and to reduce the incidence of splenectomy. However,
some patients cannot use ERT due to pain, fear of infu-
sions, poor venous access, or side effects, such as hyper-
sensitivity reactions not controllable with pre-medication
regimens and neutralizing antibodies. Miglustat, an oral
substrate reduction agent approved in Europe (2002) and
the US (2003), is recommended for symptomatic patients
with mild to moderate clinical manifestations for whom
ERT is not an option. Its use is limited, however, due to
frequent gastrointestinal side effects, especially diarrhea
[9]. Eliglustat, the most recently licensed oral SRT with
comparable efficacy to imiglucerase and a favorable safety
profile, is approved in the US (2014) and Europe (2015) as
a first-line therapy for treatment-naïve and ERT-treated
adults with GD1. Although largely free of the gastrointes-
tinal side effects associated with miglustat, eliglustat can-
not be prescribed for individuals who are cytochrome
P450 2D6 ultra-rapid or indeterminate metabolizers, or
patients who are using essential incompatible medications
[7]. Eliglustat should be avoided in patients who are preg-
nant or breast feeding, who have advanced liver, kidney or
cardiac disease as it has not been studied in these
populations.
Despite significant health-related quality of life
(HRQOL) benefits from ERT for patients with GD1 com-
pared with no treatment, and differences in effectiveness
and adverse events between ERT and miglustat, little has
been published on long-term projected outcomes for
these treatments. Studies to date simulating the long-term
outcomes of GD1 [8, 10] are inconsistent with current ex-
perience by limiting transitions between some states (e.g.,
patients with certain symptoms could not improve) or
else those studies have not explicitly separated infor-
mation on bone manifestations from hematologic and
visceral manifestations nor did they discriminate be-
tween less and more severe bone complications, such
as bone pain and fractures.
We developed a new framework based on the Disease
Severity Scoring System (DS3), a validated measure for
evaluating GD1 severity, to address some of the limita-
tions in the current literature [11]. Our framework for de-
scribing the health states of patients treated for GD1
focuses on those aspects of treatment that impact patients’
life expectancy, quality-adjusted life expectancy, and time
spent in each health state. This article describes this
framework, consisting of health states, transition probabil-
ities between those states, and preferences for those states
(utilities), and illustrates how it can estimate the long-
term outcomes of similar patient cohorts using a Markov
state-transition model. This study uses health states based
on the DS3 to develop utilities and transition probabilities
from a real-world sample of patients diagnosed with GD1
and followed since starting ERT.
Methods
Data
The data used for study come from the DS3 Score Study
(NCT01136304) that followed 166 eligible patients
18 years and older from four investigative sites in the US
and one in Canada; 33 patients were never treated and
will be subjects for a future study. Here, we utilized data
from the 133 treated patients for whom sufficient data
were available to calculate baseline DS3 scores [12]. DS3
scores were calculated for these patients annually from
initiation of treatment for an average (standard devi-
ation) of 13.3 (6.1) years. Initially, 57 (42.9%) patients re-
ceived alglucerase, 73 (54.9%) imiglucerase, 2 (1.5%)
velaglucerase, and 1 (0.8%) miglustat. At last follow-up,
105 (78.9%) patients were receiving ERT (71 imigluce-
rase, 33 velaglucerase, and 1 taliglucerase) and 12 (9.0%)
were receiving SRT (6 miglustat and 6 eliglustat); treat-
ment was unknown or had been interrupted in the re-
mainder of patients. ERT was used in 99% of the treated
patient-years. All ERT products were assumed to have
biosimilar efficacy and therefore interchangeable.
Health states
We used the DS3 for GD1 to guide the development of
health states [11, 12]. The DS3 has been validated for
GD1 patients at least 18 years old and was designed to
capture the heterogeneous and dynamic aspects of the
disease, especially skeletal complications that clinicians
consider important when assessing disease severity. The
DS3 was developed to serve as a standardized instrument
to measure GD1 symptoms and severity (burden of dis-
ease) and to classify cohorts in GD1 clinical studies. The
DS3 has three domains that include bone disease/skeletal,
hematologic, and visceral symptoms. Each domain is mea-
sured by three or more assessment items scored by a
physician. Content, face, criterion, discriminant, construct,
and feasibility validity were deemed high by global GD1
experts and physicians treating patients with GD1 [11].
The DS3 is highly correlated with other severity measures,
such as the Clinical Global Impression (CGI) scale, the
CGI-Severity (CGI-S), and the Zimran Severity Score
Index [13, 14]. Summary information on scoring the DS3
is available in Additional file 1: Appendix 1.
The nine mutually exclusive (alive) health states are
based on GD1 severity categories defined by the total
DS3 score category (mild, moderate, marked, and severe)
and the presence or absence of bone pain (BP) or severe
skeletal complications (SSC), which include lytic lesions,
avascular necrosis, or fracture: (1) mild (0 ≤ DS3 ≤ 3.5)
with no clinical symptoms of bone disease, (2) mild with
BP, (3) mild with SSC, (4) moderate (3.5 < DS3 ≤ 6.5)
without SSC, (5) moderate with SSC, (6) marked (6.5 <
DS3 ≤ 9.5) without SSC, (7) marked with SSC, (8) severe
(9.5 < DS3 ≤ 19) without SSC, and (9) severe with SSC.
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(This rank ordering was used in the ordinal regression
analysis described below to derive transition probabil-
ities.) Thus, each health state has two dimensions to best
capture a treatment’s impact on hematologic and visceral
symptoms and on bone disease and to create homoge-
neous groups of patients within each health state. Even
though we do not conceptualize it as a health state,
splenectomy status can still influence health outcomes
in two ways: via its impact on the DS3 score, which de-
fines the health state, and via its impact on health-state
transition probabilities (as described below).
We estimated health state-specific utilities from pa-
tients enrolled in the DS3 Score Study for whom re-
sponses from the SF-36 (Version 1) questionnaire were
available [15]. DS3 and SF-36 data were not collected
consistently or at fixed time intervals in the DS3 Score
Study. As a result, only patient DS3 scores, and their
corresponding health states, that could be matched to
(the closest) SF-36 responses within a 90-day window
around the DS3 score measurements were used to derive
utilities. The original SF-36 measures were converted to
the EuroQoL EQ-5D [16] utilities for the United Kingdom
(UK) population using the method developed by Brazier
and Roberts (2004) [17].
We assumed that health-state utilities depended on
the DS3 severity category, bone pain, the presence of
SSC, and patients’ age and sex at treatment initiation as
follows:
U ¼ f D;B; S;A;Xð Þ;
where U represents utility values, D the DS3 severity
(mild, moderate, marked, severe), B the presence of bone
pain, S the presence of SSC, A the age when the patient
started treatment, and X the patient’s sex. This equation
was fitted with the generalized estimating equation
method with a Gaussian error term and the identity link
function, to account for multiple observations per
patient, using data from the DS3 Score Study;
heteroscedasticity-consistent (robust) standard errors
were estimated. Utilities were calculated from the esti-
mated regression coefficients and the values of D, B, and
S corresponding to each health state using the method
of recycled predictions [18]. The effect of bone pain was
included when calculating utilities for health states that
included SSC (see Additional file 2: Appendix 2).
Transitions between health states
Patients can remain in the same health state, transition
to more or less severe health states, or die. We assumed
that a patient’s probability of being in a particular health
state, except for death, at a particular time depends on
the health state in the previous period, the length of
time the patient was receiving treatment, and other clin-
ical characteristics as follows:
Pr Htð Þ ¼ f Ht−1;Tt ;D; Sð Þ
where H is one the nine health states described above, T
is treatment duration (1, 2, or ≥ 3 years), D is the starting
DS3 category (mild, moderate, marked, or severe), S is
the patient’s splenectomy status, and t indexes the time
period. We included T in the equation to capture the
effect of disease stabilization over time [19, 20].
This equation was fitted with the ordered logistic regres-
sion method using data from the DS3 Score Study;
heteroscedasticity-consistent (robust) standard errors were
estimated. Health states for the dependent variable were
rank ordered based on the nine disease states described
above. Although the assumption of proportional odds be-
tween categories of the dependent variable was not satisfied,
it was not possible to use the less restrictive multinomial lo-
gistic or other more robust methods due to sparse data.
Twenty-four annual health-state transition probability
matrices were calculated from the estimated ordered logistic
regression coefficients and all combinations of T (3 levels)
D (4 levels), and S (2 levels) using the method of recycled
predictions [18] (see Additional file 2: Appendix 2).
Model overview and analysis
We implemented our framework as a Markov state-
transition model in Microsoft Excel® to simulate the expe-
riences of cohorts of patients with GD1. The model
includes nine health states based on DS3 Score Study
severity categories as well as an absorbing state for death.
Patients are assigned state-specific utilities for each health
state. Except for death, patients can transition between
health states, or remain in the same state, between each
annual cycle. Although patients may have undergone
splenectomy prior to starting the model, we assumed, in
accordance with current clinical guidelines, that patients
will not undergo a splenectomy once they start receiving
treatment [21]. Total undiscounted and discounted (3.5%
per annum) quality-adjusted life years (QALYs) are calcu-
lated and a half-cycle correction is applied.
This model also includes death as an absorbing state.
We estimated age-specific GD1 mortality probabilities
from summary mortality data on patients enrolled in the
International Collaborative Gaucher Group (ICGG)
Gaucher Registry using a Gompertz survival function; the
overall GD1 life expectancy at birth was 68 years (64 years
for splenectomized patients and 72 years for nonsplenec-
tomized patients) [22]. Because the estimated mortality
risks for ages 77 years and older were smaller than the
corresponding mortality risks for the general UK popula-
tion, we applied the maximum of the GD1-specific and
the UK general population (http://www.mortality.org)
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mortality risks for any given age to the patients in the
model (see Additional file 2: Appendix 2).
To show how transition probabilities and utilities are
used to predict long-term outcomes we focused on pa-
tients in the three most common health states observed
in the DS3 Score Study data: mild with no clinical symp-
toms of bone disease (19%), moderate without SSC
(28%), and marked with SSC (28%). The analyses were
stratified by splenectomy status. Consistent with the
characteristics of the patients enrolled in a recent clin-
ical trial (ENGAGE), we assumed that 50% of the simu-
lated cohort were women and all started treatment at
32 years of age [23]. Total undiscounted and discounted
(3.5% per annum) quality-adjusted life years (QALYs) are
calculated and a half-cycle correction is applied.
Results
Health state utilities
Table 1 displays the estimated coefficients of the health
state regression equation. We found that the three broad
severity categories of moderate, marked, and severe had
increasingly larger negative effects on health-state utility
compared with the mild severity category. Bone pain
was also negatively related to utility.
Figure 1 displays the average predicted utilities for
each health state, which reflects the substantial impact
of GD1 on HRQOL, especially due to skeletal complica-
tions [24, 25]. The utility values for patients with GD1
depend on disease severity and ranged from 0.76 for pa-
tients with mild disease and no clinical symptoms of bone
disease to 0.52 for patients with severe disease with SSC;
six of the nine utility values were between 0.60 and 0.69.
These estimated utilities are all substantially below the EQ-
5D population norm for the United Kingdom of 0.86 [26].
Transition probabilities
The estimated coefficients of the health state transition re-
gression equation are presented in Table 2. Patients in the
moderate, marked with and without SSC, and severe with
and without SSC states were much more likely to be in
health states worse than mild in the next time period than
patients in the mild with BP, mild with SSC, and moderate
with SSC states. Patients with intact spleens were less
likely to transition to health states worse than mild than
those who had undergone a splenectomy.
We display, as examples, the transition probability
matrices for patients who have and have not undergone
a splenectomy prior to starting treatment (S = 0, 1) in
Tables A1 and A2, respectively, in Additional file 2:
Appendix 2. These four probability matrices, which
were computed assuming T = 1 and D =mild and T =
1 and D =moderate, indicate that a considerable pro-
portion of patients transition to less severe states, based
on the rank ordering described earlier (the probabilities
below and to the left of the diagonals in each table are typ-
ically greater than the probabilities above and to the right)
and that the probabilities of improving are greater for pa-
tients with intact spleens compared with those who have
been splenectomized. The 20 transition probability matri-
ces based on the other values of T, D, and S are available
upon request.
Projected long-term outcomes
Table 3 displays the quality-adjusted life years accrued
by the hypothetical cohorts in our model and the corre-
sponding proportions of total time spent in each health
state. Patients who started in the mild or moderate state
accrued almost one more discounted QALYs than pa-
tients who started in the marked with SSC state.
Table 1 Generalized Estimating Equation Regression Results for Health State Utility in Gaucher Disease Type 1
Mean or Proportion for estimation sample Coefficient Robust standard error 95% CI
DS3 Severity (vs. Mild)
Moderate 0.381 −0.078** 0.037 −0.150, −0.005
Marked 0.113 −0.122*** 0.042 −0.205, −0.039
Severe 0.021 −0.168** 0.055 −0.275, −0.061
Bone Pain 0.258 −0.098*** 0.034 −0.165, −0.032
Severe Skeletal Complications 0.103 0.018 0.037 −0.055, 0.090
Female 0.691 −0.049 0.030 −0.108, 0.010
Age at Treatment Initiation 53.9 −0.002* 0.001 −0.004, 0.001
Constant 0.880*** 0.078 0.727, 1.033
Number of Observations 97
Number of Patients 50
***p < 0.01, **p < 0.05, *p < 0.10
Abbreviations: CI confidence interval, DS3 disease severity scoring system
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Patients with intact spleens who started treatment in
the mild or moderate state spent more of their lifetimes
in time in the mild to moderate states (about 99%) than
patients who started treatment in the marked plus SSC
state (about 94%). Similar patterns are seen for patients
who were splenectomized, except that those who started
treatment in the marked plus SSC state spent less of
their lifetimes in the mild state (about 20%) than those
who started treatment in the marked plus SSC state with
intact spleens (about 34%).
We compared the distribution of health states over time
predicted by the model to the actual experiences of the
patients in the DS3 Score Study. Table A3 in Additional
file 2: Appendix 2 displays these distributions for patients
starting treatment in the mild, moderate, and marked with
SSC health states. Due to sample size limitations, we only
Table 2 Ordered Logistic Regression Results for Annual Health-State Transitions in Gaucher Disease Type 1
Proportion for estimation sample Coefficient Robust standard error 95% CI
Health State in Previous Year (vs. Mild)
Mild + Bone Pain 0.114 1.305*** 0.241 0.833, 1.777
Mild + SSC 0.010 0.840* 0.452 −0.046, 1.727
Moderate 0.344 2.581*** 0.305 1.983, 3.179
Moderate + SSC 0.041 1.253*** 0.381 0.506, 2.000
Marked 0.028 4.504*** 0.465 3.593, 5.416
Marked + SSC 0.062 3.617*** 0.462 2.711, 4.524
Severe 0.003 4.213*** 0.698 2.845, 5.581
Severe + SSC 0.007 6.072*** 1.374 3.380, 8.765
Years on Treatment (vs. One Year)
Two Years 0.086 0.293 0.361 −0.414, 000
Three or More Years 0.807 0.315 0.305 −0.283, 0.913
Baseline DS3 Category (vs. Mild)
Moderate 0.312 −0.150 0.276 −0.691, 0.391
Marked 0.410 0.873*** 0.274 0.336, 1.410
Severe 0.071 1.349*** 0.411 0.543, 2.154
Not Splenectomized 0.672 −1.089*** 0.250 −1.578, −0.599
Ordered Logistic Cutpoints
Cutpoint 1 0.740 0.456 −0.153, 1.634
Cutpoint 2 1.662*** 0.464 0.752, 2.572
Cutpoint 3 1.727*** 0.467 0.812, 2.641
Cutpoint 4 5.054*** 0.519 4.037, 6.070
Cutpoint 5 5.835*** 0.523 4.810, 6.861
Cutpoint 6 6.577*** 0.633 5.335, 7.818
Cutpoint 7 8.808*** 0.639 7.555, 10.060
Cutpoint 8 9.066*** 0.650 7.792, 10.340
Number of Patients 130
Number of Observations 970
Standard errors account for multiple observations per patient. *** p < 0.01, **p < 0.05, *p < 0.10
Abbreviations: CI confidence interval, SSC severe skeletal complications
Fig. 1 Predicted Health State Utilities in Gaucher Disease Type 1. Note:
Error bars correspond to robust 95% confidence intervals
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compared patients who had not undergone splenectomy.
Overall, the predictions matched the observed data rea-
sonably well given the limited sample size, but the predic-
tions did deviate from the observed data in some cases.
Discussion
This research presents a new framework to describe the
course of GD1 for treated patients. This framework ex-
tends the literature by presenting newly defined GD1
health states, their corresponding utility values, and
health-state transition probabilities based on the DS3
that were derived from a single real-word sample
followed since starting ERT. The Markov model uses
these health states and parameters to simulate the long-
term outcomes of three cohorts upon starting treatment.
Our newly defined health states are based on the DS3, a
measure developed to specifically assign weights to the as-
pects of GD1 that clinicians consider important when
assessing disease severity. These health states extend pre-
vious work [8, 10] by showing that patients’ health status
and HRQOL can deteriorate or improve over time and
that these transitions are influenced by splenectomy status
and disease severity when starting treatment. These health
states also capture the hematologic and visceral dimen-
sions of the disease separately from the bone dimension,
which help to characterize the disease and its response to
treatment. For example, Charrow and Scott emphasized
that hematologic parameters, liver and spleen volumes,
and bone disease do not necessarily respond to treatment
to the same extent or at the same time and that response
may be affected by timing of treatment initiation, enzyme
dose, and the presence of irreversible complications such
as osteonecrosis [27]. Deegan et al. and Weinreb et al.
have also shown that patients can still experience
significant bone complications after starting ERT [12, 28],
even as overall disease burden, measured by the DS3, has
decreased over time [12].
We found that treated GD1 patients reported lower
levels of HRQOL as measured by EQ-5D utilities, than
the general population and that those utilities ranged from
0.76 for the mild health state to 0.52 for severe with SSC.
Although these estimated utility values are consistent with
the study by Deegan et al. that reported a lower median
EQ-5D values (0.68 and 0.63) for patients who ever had
osteonecrosis or who suffered a frailty fracture than those
who had neither (0.80) despite ongoing ERT [28], our
values tend to be lower than those reported by van Dussen
et al., which ranged from 0.72 to 0.93, except for malig-
nancy, which was 0.15 [8]. Our values may be lower than
those reported by van Dussen et al. for a number of rea-
sons: our states may already include attributes of the states
used by van Dussen et al., the characteristics of the sam-
ples were different, the direct use of the EQ-5D by van
Dussen et al. rather than our use of EQ-5D utilities
mapped from responses to the SF-36, and different recall
periods inherent in the HRQOL instruments used. It
should be noted, however, that the difference between the
asymptomatic and bone complications health states
(−0.07) reported by van Dussen et al. was similar to the
difference we observed due to SSC (−0.08).
Utilities for health states involving bone complications
were typically lower than utilities for health states without
bone complications. For example, the average utilities for
the mild and moderate health states were 0.76 and 0.67,
whereas they were 0.67 and 0.61 for the mild with BP and
moderate with SSC states. These utilities can be used in
future economic evaluations to calculate QALYs of com-
peting GD1 therapies. We also have estimated a function
Table 3 Model Results (Projected Lifetime Outcomes) in Gaucher Disease Type 1
Starting Health State
Intact Spleen No Spleen
Mild Moderate Marked with SSC Mild Moderate Marked with SSC
Discounted QALYs 15.73 15.69 14.92 15.70 15.65 14.89
Undiscounted QALYs 31.16 31.20 29.73 31.13 31.16 29.71
% of Remaining Lifetime Spent in:
Mild 69.72 70.61 33.86 68.94 69.57 19.55
Mild with BP 12.86 12.26 16.13 13.15 12.23 13.37
Mild with SSC 0.73 0.69 1.17 0.75 0.70 1.07
Moderate 15.69 15.58 42.20 16.14 16.50 52.97
Moderate with SSC 0.53 0.46 2.76 0.55 0.54 5.40
Marked 0.24 0.21 1.36 0.25 0.24 3.01
Marked with SSC 0.20 0.17 2.38 0.21 0.20 3.02
Severe 0.01 0.00 0.03 0.01 0.01 1.28
Severe with SSC 0.02 0.02 0.12 0.02 0.02 0.33
Results for cohorts starting treatment at age 32 (patients in all cohorts have 42.29 remaining life years). QALYs discounted 3.5% per annum
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that predicts transition probabilities among these health
states conditional on time on treatment, disease severity
when starting treatment, and splenectomy status that is
consistent with other studies of the course of the GD1,
onset of action, and duration of treatment effect [19, 20,
29–32]. This function can be used to derive the transition
probability matrices needed to project short- and long-
term outcomes of patients after starting treatment.
The results presented here should be interpreted in
light of the limitations of this research. Although this
framework is meant to capture the most salient clinical
aspects of GD1, it does simplify a complex disease and
does not capture disease progression for patients not re-
ceiving treatment. The health states may have been dif-
ferent if we based them on another validated GD1
severity measure. However, other measures, such as the
Gaucher Disease Severity Index-Type I [33], may not be
as readily available or easy to use in clinical practice and
research studies as the DS3. The uncertainty surround-
ing the point estimates for the health-state utilities are
due, in part, to the relatively small numbers of patients
observed in some health states and the way in which
they were estimated. Rather than eliciting EQ-5D utility
values directly from patients, the utilities were derived
from SF-36 scores, which were not always measured at
the same time that DS3 scores were assessed. Similarly,
methods other than the ordered logistic regression ap-
proach may have produced different health-state transi-
tion probabilities. The data presented here are based on
patients who were predominantly treated with ERT (imi-
glucerase in about half the cases). The extent to which
the utility values results differ for other treatments is un-
clear in the absence of information on the disutility asso-
ciated with intravenous therapy. Furthermore, without
data from head-to-head studies assessing the efficacy of
imiglucerase compared with other treatments, as well as
of different doses and administration intervals, we do
not know if the transition probabilities differ for other
treatments. Finally, because this framework was devel-
oped to compare different treatment options, it lacks
data on the (untreated) natural history of GD1.
Despite these limitations, the framework and data pre-
sented here contribute to the literature evaluating GD1
treatments by providing new information on the pre-
dicted long-term clinical outcomes of patients after
starting treatment. This framework can be updated to
accommodate data on the relative real-world efficacy of
treatment options, such as eliglustat [23, 34, 35], as they
become available. Although we did not include the use
of healthcare services, and their associated costs, or
other aspects of treatment, such as adverse events and
treatment discontinuation/switching, these factors can
be included in a full cost-effectiveness analyses within a
local context.
Conclusions
We have developed a new framework that can be used to
project the long-term outcomes of GD1 patients starting
treatment. This framework, along with the data presented
here, is comprised of newly defined GD1 health states,
and their corresponding utility values, and health-state
transition probabilities based on the DS3. This framework
can also be used to evaluate multiple GD1 treatments and
can be updated to accommodate data on the relative real-
world efficacy of GD1 treatment options.
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